VEGFA and adenocarcinoma: Among non-small cell lung cancer (NSCLC), the subtype adenocarcinoma is associated with a higher risk of VTE (20, 21) and this risk might be increased by chemotherapy and other systemic treatments such as molecules interfering with the vascular endothelial growth factor (VEGF) pathway (9).